Pre-made Duvortuxizumab benchmark antibody ( Bispecific scFv with Crossover, anti-CD19;CD3E therapeutic antibody, Anti-B4/CVID3;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-161

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-161 Category Tags ,

Product Details

Pre-made Duvortuxizumab benchmark antibody (Bispecific scFv with Crossover, anti-CD19;CD3E therapeutic antibody, Anti-B4/CVID3;T3E/TCRE/IMD18 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Duvortuxizumab (INN[1]) is a chimeric/humanized monoclonal antibody designed for the treatment of B-cell malignancies.[2]

Products Name (INN Index)

Pre-Made Duvortuxizumab biosimilar, Bispecific scFv with Crossover, Anti-CD19;CD3E antibody: Anti-B4/CVID3;T3E/TCRE/IMD18 therapeutic antibody

INN Name

Duvortuxizumab

Target

CD19,CD3E

Format

Bispecific scFv with Crossover

Derivation

Bispecific antibody

Species Reactivity

Human

CH1 Isotype

NA

VD LC

Kappa,Lambda

Highest_Clin_Trial (Jan '20)

Phase-I

Est. Status

Discontinued

100% SI Structure

None;None

99% SI Structure

None;None

95-98% SI Structure

None;None

Year Proposed

2016

Companies

Janssen Biotech,MacroGenics

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

Diffuse large B cell lymphoma,Follicular lymphoma,Non-Hodgkin's lymphoma,Precursor B-cell lymphoblastic leukaemia-lymphoma

Development Tech

Dual-Affinity?Re-targenting (DART?)

Previous Name

NA

Gm Offical Target Name

CD19,CD3E

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide